Bloomberg Subscription
A low-cost, widely used anti-inflammatory drug improved survival in patients with COVID-19, the first treatment to show life-saving promise months into the pandemic.
Deaths among patients who needed breathing assistance were lower over a period of four weeks when they received the 60-year-old medicine dexamethasone, University of Oxford researchers said Tuesday. The study was stopped early because of its crucial findings.
Doctors and companies are scouring for treatments that can help patients survive the new coronavirus, which has killed more than 400,000 people worldwide. Gilead Sciences Inc.’s antiviral remdesivir, which has approval to treat COVID-19, has only demonstrated the ability to shorten patients’ recovery.
Read More →